McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Patent Docs: FDA approves Sandoz’s filgrastim biosimilar drug product” that appears in the May 2015 online edition of DDNEWS. Recently, the U.S. Food and Drug Administration (FDA) approved a biosimilar version of Amgen’s Neupogen (filgrastim) product for sale in the United States. This is the first biosimilar to be approved under the provisions of the Biologics Price Competition and Innovation Act (BPCIA), which was part of the healthcare reform package passed in 2010 and commonly referred to as Obamacare. Sandoz, (a division of Novartis) will sell its biosimilar under the brand name Zarxio. view the article